TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02286531
Drug: O-(2[18F]FLUOROETHYL)-L-TYROSINE
Normalized name: 3-hydroxy-O-phosphono-L-tyrosine
DrugBank: Foslevodopa (DB16683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
Study: NCT02792816
Drug: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
Study: NCT02789150
Drug: Norepinephrine (Levophed)
Normalized name: norepinephrine Injection [Levophed]
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrate norepinephrine to MAP 65-70
Study: NCT02789150
Drug: Norepinephrine (Levophed)
Normalized name: norepinephrine Injection [Levophed]
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titrate norepinephrine to MAP 85 or greater
Study: NCT05122234
Drug: Standard treatment of Covid-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of Covid-19 based on national protocol.
Study: NCT02790528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug will be administered.
Study: NCT00030342
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02670083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study: NCT02456428
Drug: Insulins
Normalized name: INSULINS AND ANALOGUES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
Study: NCT02870582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best support treatment
Study: NCT02456428
Drug: Alpha-glucosidase inhibitors
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT00150592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03093025
Drug: TS-121 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally taken once daily
Study: NCT03093025
Drug: TS-121 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally taken once daily
Study: NCT03093025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally taken once daily
Study: NCT01438060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
Study: NCT01218360
Drug: Physician standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
Study: NCT01325740
Drug: STX107
Approvals — FDA: no, EMA: no, PMDA: no
Description: STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
Study: NCT01532414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule taken one time daily for 3 months
Study: NCT04072302
Drug: KAF156
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet
Study: NCT04072302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet
Study: NCT02252016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
Study: NCT04275349
Drug: Xingnaojing injection within 24 hours of symptom onset
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
Study: NCT02521701
Drug: NFL101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL.
Study: NCT00880815
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03118297
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
Study: NCT01394445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg
Study: NCT01512628
Drug: Pentaspan, voluven, volulyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
Study: NCT03147053
Drug: Jiedu Tongluo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
Study: NCT03147053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
Study: NCT00482612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
Study: NCT03574805
Drug: PRS-060
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug
Study: NCT03574805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalant designed to mimic PRS-060
Study: NCT01956812
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
Study: NCT00672373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat flour placebo capsule,1 capsule tid, po,12 weeks
Study: NCT02450487
Drug: Piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
Study: NCT03717701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take inert tablets similar in appearance, color, and consistency
Study: NCT00991796
Drug: CS-1008
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
Study: NCT00991796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02108353
Drug: Melatonin 2mg
Normalized name: Vicks ZzzQuil PURE Zzzs Melatonin 2mg Extended-Release Tablet
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
Study: NCT02108353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
Study: NCT03876444
Drug: Intravenous Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Methylprednisolone will be used in the intervention group
Study: NCT03876444
Drug: Oral Pednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Prednisolone will be used in the Control Group
Study: NCT03742349
Drug: NIR178
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT01200784
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage
Study: NCT02278302
Drug: Aggrenox®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02278302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04418219
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
Study: NCT00684307
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER tablet, PO, once daily for a period of 3-9 months.
Study: NCT00684307
Drug: AZD0837
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER tablet, PO, twice daily for a period of 3-9 months
Study: NCT00272441
Drug: inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06251349
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: postoperative treatment with diclofenac to prevent HO
Study: NCT01174849
Drug: Prevenar13
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium.
Study: NCT01174849
Drug: COMBO
Normalized name: Comboguard
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
Study: NCT00275184
Drug: Citramag powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02118688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03178487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00004900
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01285908
Drug: Intravenous Norepinephrine Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00835588
Drug: PROTONIX® 40 mg delayed-release tablets.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 40 mg
Study: NCT00295490
Drug: Devil Claw
Normalized name: DEVILS CLAW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose ranging study so will elucidate dose Frequency is four times daily
Study: NCT00295490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo has same dosing freq as for active intervention and for same time period
Study: NCT02353936
Drug: BIBW2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily
Study: NCT00223093
Drug: TAIZ
Normalized name: ALCOHOL 400 mL in 500 mL TOPICAL LIQUID [Miracle Power Hand Sanitaizer]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00406393
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
Study: NCT01983735
Drug: TELMINUVO Tab. (80/2.5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks.
Study: NCT01983735
Drug: TELMINUVO Tab. (80/5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks.
Study: NCT01022190
Drug: Etoricoxib (Arcoxia)
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
Study: NCT00244023
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
Study: NCT00244023
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
Study: NCT02426450
Drug: 5-Fluorouracil/Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks
Study: NCT01640743
Drug: Tacrolimus + Methylprednisolone
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
Study: NCT04418765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: concentrate for solution for infusion, intravenously
Study: NCT01640743
Drug: Tacrolimus + Everolimus + Methylprednisolone
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
Study: NCT04797936
Drug: BNO 1030
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imupret 25 drops х 6 times per day for 14 days
Study: NCT03130790
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study: NCT03130790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study: NCT00341250
Drug: AMA1-C1/Alhydrogel Malaria Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01077973
Drug: Novel Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
Study: NCT01077973
Drug: Standard Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of standard ibuprofen (400mg) plus placebo
Study: NCT01077973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of placebo
Study: NCT00415779
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2 mg IV every 2 weeks
Study: NCT04090658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
Study: NCT00080782
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral celecoxib twice daily in the absence of disease progression.
Study: NCT00080782
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: By vein (IV) over 30 minutes on days 1, 8, 15, and 22
Study: NCT01392820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, twice daily
Study: NCT02364986
Drug: Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebif® 44µg (day 1, 3, 5 and 8) s.c.
Study: NCT02517424
Drug: High THC/Low CBD Cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried cannabis
Study: NCT02517424
Drug: Low THC/Low CBD Cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried cannabis
Study: NCT00901719
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
Study: NCT00314106
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/ day x 2 days intravenous
Study: NCT03485118
Drug: HS006+CHOP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Study: NCT03485118
Drug: HS006+CHOP
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle.
Study: NCT01975545
Drug: Fluor varnish
Normalized name: Fluor a Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental varnish will be applied to one anterior superior teeth in a random side.
Study: NCT01975545
Drug: Fluor varnish with nanoparticles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
Study: NCT04479800
Drug: ASTX660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: capsule; Route of administration: oral
Study: NCT02956993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03175549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo pills taken orally for 14 days
Study: NCT00208091
Drug: Botulinum toxin, type B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
Study: NCT00022087
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
Study: NCT01559116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching tiotropium+olodaterol FDC
Study: NCT00562718
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes